UC San Diego César E. Chávez Celebration |
This April, UC San Diego is dedicated to honoring the life and achievements of César E. Chávez. The month-long celebration begins with the César E. Chávez Celebration Kickoff and Scholarship Awards on April 4, which will feature live performances and a keynote address from UC Regent John A. Pérez. Sign up for free programs that will reflect the theme "Celebrando y Luchando por La Causa; Celebrating and Fighting for the Cause."
|
American Association for Cancer Research (AACR) Annual Meeting |
April 5 - 10, 2024 | San Diego, California |
The American Association for Cancer Research (AACR) Annual Meeting will take place in San Diego starting on April 5, 2024, and Moores Cancer Center Members will be presenting over 60 sessions.
The AACR Annual Meeting highlights the work of the best minds in cancer research and care from institutions worldwide and serves as an opportunity for Moores Members to connect with thousands of like-minded experts in the field, who range from postdocs to mid-career scientists.
Moores will exhibit a booth at the Cancer Biomedical Research Fair to recruit top researchers, clinicians, clinical trialists, postdocs, and fellows on Saturday, April 6, from 9:00 a.m. to 3:00 p.m. Moores leadership is seeking faculty volunteers to represent Moores at the booth. If you are interested in volunteering, then please take a moment to fill out this form.
Not seeing your session or poster listed? Email Yariela Freeman (yfreeman@health.ucsd.edu) to have yours added.
|
American Cancer Society Cancer Prevention Research Conference |
June 25 - 27, 2024 | Boston, Massachusetts |
Registration is now open for the Cancer Prevention Research Conference, which will feature sessions that explore health inequalities in cancer incidence and prevention, mechanistic insights in prevention strategies, and precision prevention in high-risk populations.
|
Cell Atlases as Roadmaps in Cancer: 2024 Joint Distinguished Moores Cancer Center & UC San Diego Department of Pharmacology Annual Lecture |
On Thursday, April 4, 2024, at 12:00 p.m., Aviv Regev, PhD, will present “Cell Atlases as Roadmaps in Cancer." This topic is featured in the 2024 annual joint distinguished lecture between Moores Cancer Center and the UC San Diego Department of Pharmacology.
|
The Complexities of Tumor Associated Macrophages and the Key to Effective Targeting for Anti-Cancer Therapy: A Talk with Immunologist Jennifer Guerriero, PhD |
On Friday, April 5, from 12:00 p.m. to 1:00 p.m., Harvard professor and immunologist, Jennifer Guerriero, PhD, will present "The Complexities of Tumor Associated Macrophages and the Key to Effective Targeting for Anti-Cancer Therapy."
|
|
|
April 2, 2024 | 12:00 pm
Leichtag Biomedical Research Building Room 107
|
April 5, 2024 | 12:00 p.m.
Leichtag Biomedical Research Building Room 107
|
April 9, 2024 | 7:05 p.m.
Petco Park
|
April 10, 2024 | 3:00 to 4:00 p.m.
Duane Roth Auditorium, Sanford Consortium for Regenerative Medicine
|
Mateo Banegas, PhD | Angelique Richardson MD, PhD |Melody Schiaffino, PhD, MPH |
April 11, 2024 | 4:30 to 7:00 p.m.
SDSU Alumni Center
|
April 17, 2024 | 12:00 p.m.
Comer Commons
|
May 10, 2024 | 12:00 to 1:00 p.m.
Comer Commons
|
Juan F. Javier-DesLoges, MD, MS |
May 1, 2024 | 12:00 p.m.
Comer Commons
|
|
|
Special Trainee Opportunity | Resilience in Academia: Getting Personal with Jennifer Guerriero, PhD |
Join Dr. Jennifer Guerriero on Thursday, April 4, from 10:00 a.m. to 11:00 a.m. to learn about her journey in medicine and academia. Her presentation will include advice on non-linear career trajectories, mentoring, job markets, personal life sacrifices, building a family during academic training, supporting peers, creating opportunities, and networking. Time will be allotted for questions and discussion.
|
CRTEC Speed Mentoring Workshop |
April 11, 2024 | 12:00 to 1:00 p.m. |
Join us to get expert advice from San Diego State University and UC San Diego faculty members Drs. Leonardo Nogueria, Teresa Monkkonen, and Hari Narayan!
|
Surgical Oncologists As Scientists (SOAS) Training Program |
Designed for the next generation of translational surgeon-scientists, SOAS provides rigorous training in three disciplines: (1) the tumor microenvironment; (2) techniques of biobanking; (3) innovation and entrepreneurship. This unique training program features 18 NIH-funded ($28.1 million per year; $18.5 million in direct costs) Faculty Mentors. Applications to participate in SOAS must be submitted by April 15, 2024.
|
Cancer Therapeutics Training (CT2) Training Program |
The CT2 Training Program is open to both MDs and PhDs and provides an intensive 2-year period of research and training in the development of novel cancer therapeutics or diagnostics at Moores. CT2 trainees not only execute a research program under the direction of a Moores Member, but also participate in coursework, seminars, and lectures. CT2 graduates are prepared to transition to leadership roles in cancer therapeutics development in either an academic or commercial environment. Applications to participate in CT2 must be submitted by April 15, 2024.
|
|
|
FEATURED FUNDING OPPORTUNITIES |
Department of Defense (DOD) Pre-Announcements for Funding Opportunities |
The DOD Peer Reviewed Cancer Research Program (PRCRP) features the following funding opportunities:
|
- Advancing Clinical Care Through Clinical Trials Award
- Career Development Award – Scholar Option
- Convergent Science Cancer Consortium Award
- Idea Award
- Impact Award
- Patient Well-Being and Survivorship Award
- Virtual Cancer Center Director Award
|
The DOD Breast Cancer Research Program (BCRP) features the following funding opportunities:
|
- Breakthrough Award Levels 1 and 2
- Breakthrough Award Level 3
-
Breakthrough Award Level 4
- Clinical Research Extension Award
- Era of Hope Scholar Award
- Transformative Breast Cancer Consortium Award
- Transformative Breast Cancer Consortium Development Award
|
Although the Breakthrough Award Level 3, Breakthrough Award Level 4, and Transformative Breast Cancer Consortium Award mechanisms have been released twice per fiscal year in past years, these three mechanisms likely will be released once for FY24. If interested in applying to these three FY24 mechanisms, then investigators are strongly encouraged to apply to the current funding opportunities for which pre-applications are due May 14, 2024
|
The DOD Lung Cancer Research Program (LCRP) features the following funding opportunities:
|
- Concept Award
- Career Development Award
- Idea Development Award
- Translational Research Award
- Patient-Centered Outcomes and Survivorship Award
|
The DOD Ovarian Cancer Research Program (OCRP) features the following funding opportunities:
|
- Pilot Award
- Investigator- Initiated Research Award
- Clinical Trial Award
- Clinical Trial Translational Endpoints Research Award ** (NEW)
- Ovarian Cancer Academy – Leadership Award
- Ovarian Cancer Academy – Early-Career Investigator Award
|
|
|
|
Nuclear morphology is shaped by loop-extrusion programs |
Huan-You Wang, MD, PhD (Hematologic Malignancies), Kathleen Fisch, PhD (Structural and Functional Genomics), Cornelis Murre, PhD (Hematologic Malignancies)
|
|
|
| Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress |
Xiaoyu Zhao, PhD (Structural and Functional Genomics), Trey Ideker, PhD (Structural and Functional Genomics)
|
|
|
| Peptide-Driven Proton Sponge Nano-Assembly for Imaging and Triggering Lysosome-Regulated Immunogenic Cancer Cell Death |
Nicole Steinmetz, PhD (Solid Tumor Therapeutics), Tariq Rana, PhD (Solid Tumor Therapeutics), Jesse Jokerst, PhD (Solid Tumor Therapeutics)
|
|
|
CLINICAL TRIALS OFFICE (CTO) |
NKT2152-202: A Phase 2 Trial to Evaluate the Safety and Efficacy of NKT2152 in Combination with Palbociclib (Doublet) and with Palbociclib and Sasanlimab (Triplet) in Subjects with Advanced or Metastatic Clear Cell Renal Cell Carcinoma |
PI: Rana McKay, MD
NCT: NCT05119335
|
HC366-RCC2311 / MK-6482-030: A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC7366 in Combination with Belzutifan (WELIREGTM) in Patients with Locally Advanced (Inoperable) or Metastatic Renal Cell Carcinoma |
PI: Rana McKay, MD
NCT: NCT06234605
|
CLINICAL TRIALS OFFICE (CTO) TRANSFORMATION INITIATIVE |
-
PI Research KPIs for Q1 will be reviewed over the next 2 weeks, after which each PI’s score will be rewarded with an incentive Z payment to the PI Discretionary Account. If you are a PI without a discretionary account set up, then instructions will be provided no later than next week on how to request one, which will include an email template to make this simple for you.
-
To date, CTO has hired over 30 NewCo positions to date, with more offers in progress. See table below for positions that CTO is actively recruiting. If you have interest in or know experienced candidates for any of these roles, then please apply or pass a referral to CTO.
- The CTO Fast Lane initiative has resulted in the accelerated activation of 40 trials to date through the outstanding efforts of the SWAT team—thank you to all involved.
- Congratulations to Lisa Kim, Michelle Padilla, and Kayleigh Hernandez for new roles as CTO Training & Education Specialists. If you have any questions related to upcoming training sessions or requests for upcoming training topics, then please reach out to them.
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT |
|
|
Jackie Robinson YMCA Health Fair
|
April 3, 2024 | 10:00 a.m. to 3:00 p.m. |
Join COE at the Jackie Robinson YMCA Health Fair (151 YMCA Way, San Diego, CA 92102) on Wednesday, April 3, from 10:00 a.m. to 3:00 p.m. This event will spotlight colorectal cancer and feature a large interactive inflatable colon for attendees to walk through. If you would like to assist COE at this event, then please contact COE at mcccoe@health.ucsd.edu.
|
|
|
|